Boston Scientific 10-Q 2026-09-30
BSX · CIK 885725 · Form 10-Q · Period ended September 30, 2026 · Filed November 2, 2026
Revenue rose 1.4% to $5.14 billion. Operating margin was 16.1%, against 20.7% a year earlier.
8 sections, 255K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 30, 2026 | Quarter ended Sep 30, 2025 | Change |
|---|---|---|---|
| Revenue | $5.14B | $5.07B | +1.4% |
| Operating income | $828M | $1.05B | -21.0% |
| Diluted EPS | $0.40 | $0.51 | -21.6% |
| Cash and equivalents | $609M | n/a | n/a |
| Operating margin* | 16.1% | 20.7% | -4.6 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
OR
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 04-2695240 | |||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
300 Boston Scientific Way**,** Marlborough**,** Massachusetts 01752-1234
(Address of Principal Executive Offices) (Zip Code)
508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock, par value $0.01 per share | BSX | New York Stock Exchange | ||||||||||||
| 0.625% Senior Notes due 2027 | BSX27 | New York Stock Exchange | ||||||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☑ | Accelerated filer | ☐ | ||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The number of shares outstanding of Common Stock, $0.01 par value per share, as of October 29, 2026 was 1,449,473,222.
TABLE OF CONTENTS
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (this Quarterly Report) contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements include, among other things, statements regarding our financial and operating performance; acquisitions; clinical trials; business plans and product performance; new and anticipated product approvals and launches; intellectual property; regulations and accounting pronouncements; legal proceedings; tax matters and regulations; and macroeconomic and geopolitical conditions. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.
The forward-looking statements in this Quarterly Report are based on certain risks and uncertainties, including the risk factors described in Item 1A under the heading Risk Factors in our most recent Annual Report on Form 10-K and the specific risk factors discussed herein and in connection with forward-looking statements made throughout this Quarterly Report, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Quarterly Report. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events, including the impacts of the cybersecurity incident first reported on August 26, 2026 on our operations and financial results; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our prior and new restructuring programs; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve sustainability goals; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Item 1A. Risk Factors in our most recent Annual Report on Form 10-K, which we may update in Part II, Item 1A. Risk Factors in Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this Quarterly Report.
PART I
FINANCIAL INFORMATION
Item 1. CONSOLIDATED FINANCIAL STATEMENTS
BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (in millions, except per share data) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net sales | $ | 5,138 | $ | 5,065 | $ | 15,784 | $ | 14,788 | |||||||||||||||
| Cost of products sold (excluding amortization expense) | 1,710 | 1,523 | 4,894 | 4,613 | |||||||||||||||||||
| Gross profit | 3,428 | 3,542 | 10,890 | 10,175 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Selling, general and administrative expenses | 1,683 | 1,741 | 5,266 | 5,053 | |||||||||||||||||||
| Research and development expenses | 520 | 514 | 1,589 | 1,483 | |||||||||||||||||||
| Royalty expense | 12 | 12 | 37 | 40 | |||||||||||||||||||
| Amortization expense | 234 | 225 | 699 | 669 | |||||||||||||||||||
| Intangible asset impairment charges | 39 | 0 | 39 | 46 | |||||||||||||||||||
| Contingent consideration net expense (benefit) | (32) | 11 | (78) | 11 | |||||||||||||||||||
| Restructuring net charges (credits) | 63 | (8) | 74 | 85 | |||||||||||||||||||
| Litigation-related net charges (credits) | 81 | — | 157 | — | |||||||||||||||||||
| 2,600 | 2,494 | 7,783 | 7,387 | ||||||||||||||||||||
| Operating income (loss) | 828 | 1,048 | 3,107 | 2,788 | |||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||
| Interest expense | (100) | (87) | (285) | (259) | |||||||||||||||||||
| Other, net | 4 | (23) | 133 | 156 | |||||||||||||||||||
| Income (loss) before income taxes | 733 | 939 | 2,955 | 2,685 | |||||||||||||||||||
| Income tax expense (benefit) | 153 | 183 | 132 | 463 | |||||||||||||||||||
| Net income (loss) | 580 | 755 | 2,823 | 2,222 | |||||||||||||||||||
| Net income (loss) attributable to noncontrolling interests | (2) | (0) | (6) | (4) | |||||||||||||||||||
| Net income (loss) attributable to Boston Scientific common stockholders | $ | 582 | $ | 755 | $ | 2,830 | $ | 2,226 | |||||||||||||||
| Net income (loss) per common share — basic | $ | 0.40 | $ | 0.51 | $ | 1.93 | $ | 1.50 | |||||||||||||||
| Net income (loss) per common share — diluted | $ | 0.40 | $ | 0.51 | $ | 1.92 | $ | 1.49 | |||||||||||||||
| Weighted-average shares outstanding | |||||||||||||||||||||||
| Basic | 1,448.7 | 1,481.7 | 1,468.0 | 1,479.6 | |||||||||||||||||||
| Diluted | 1,452.0 | 1,495.5 | 1,473.9 | 1,494.0 |
Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding.
BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (in millions) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net income (loss) | $ | 580 | $ | 755 | $ | 2,823 | $ | 2,222 | |||||||||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||||||||
| Foreign currency translation adjustment | (6) | (28) | 212 | (719) | |||||||||||||||||||
| Net change in derivative financial instruments | (37) | 62 | 56 | (238) | |||||||||||||||||||
| Net change in defined benefit pensions and other items | (0) | (0) | 0 | (1) | |||||||||||||||||||
| Other comprehensive income (loss) | (44) | 34 | 268 | (957) | |||||||||||||||||||
| Comprehensive income (loss) | $ | 537 | $ | 789 | $ | 3,092 | $ | 1,265 | |||||||||||||||
| Net income (loss) attributable to noncontrolling interests | (2) | (0) | (6) | (4) | |||||||||||||||||||
| Other comprehensive income (loss) attributable to noncontrolling interests | 3 | 1 | 10 | 7 | |||||||||||||||||||
| Comprehensive income (loss) attributable to noncontrolling interests | 1 | 1 | 4 | 3 | |||||||||||||||||||
| Comprehensive income (loss) attributable to Boston Scientific common stockholders | $ | 536 | $ | 788 | $ | 3,088 | $ | 1,262 |
Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding.
BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
| As of | |||||||||||
| (in millions, except share and per share data) | September 30, 2026 | December 31, 2025 | |||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 609 | $ | 1,965 | |||||||
| Trade accounts receivable, net | 3,113 | 2,926 | |||||||||
| Inventories | 3,317 | 2,943 | |||||||||
| Prepaid income taxes | 381 | 299 | |||||||||
| Other current assets | 745 | 660 | |||||||||
| Total current assets | 8,164 | 8,794 | |||||||||
| Other investments | 2,292 | 681 | |||||||||
| Property, plant and equipment, net |
Showing the first 8K of 164K characters. Open the full section
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Introduction
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body. We advance science for life by providing a broad range of high-performance solutions to address unmet patient needs and reduce the cost of healthcare. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.
Executive Summary
The following section describes some of our financial highlights and trends on a consolidated basis. For additional information on our business units and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K.
| (in millions, except percentages and per share data) | Three Months Ended September 30, | 2026 versus 2025 | 2026 versus 2025 | ||||||||||||||||||||
| 2026 | 2025 | $ | % | ||||||||||||||||||||
| Reported net sales | $ | 5,138 | $ | 5,065 | $ | 74 | 1.5 | % | |||||||||||||||
| Reported net income (loss) attributable to Boston Scientific common stockholders | 582 | 755 | (173) | (22.9) | % | ||||||||||||||||||
| Adjusted net income (loss) attributable to Boston Scientific common stockholders (non-GAAP measure) | 1,063 | 1,124 | (62) | (5.5) | % | ||||||||||||||||||
| Net income (loss) per common share — diluted | 0.40 | 0.51 | (0.10) | (20.6) | % | ||||||||||||||||||
| Adjusted net income (loss) per common share — diluted (non-GAAP measure) | 0.73 | 0.75 | (0.02) | (2.6) | % |
| (in millions, except percentages and per share data) | Nine Months Ended September 30, | 2026 versus 2025 | 2026 versus 2025 | ||||||||||||||||||||
| 2026 | 2025 | $ | % | ||||||||||||||||||||
| Reported net sales | $ | 15,784 | $ | 14,788 | $ | 995 | 6.7 | % | |||||||||||||||
| Reported net income (loss) attributable to Boston Scientific common stockholders | 2,830 | 2,226 | 603 | 27.1 | % | ||||||||||||||||||
| Adjusted net income (loss) attributable to Boston Scientific common stockholders (non-GAAP measure) | 3,527 | 3,372 | 155 | 4.6 | % | ||||||||||||||||||
| Net income (loss) per common share — diluted | 1.92 | 1.49 | 0.43 | 28.8 | % | ||||||||||||||||||
| Adjusted net income (loss) per common share — diluted (non-GAAP measure) | 2.39 | 2.26 | 0.14 | 6.0 | % |
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 versus 2025 | 2026 versus 2025 | ||||||||||
| Net sales reported growth | 1.5 | % | 6.7 | % | |||||||
| Impact of foreign currency fluctuations | 0.0 | % | (0.9) | % | |||||||
| Net sales operational growth (non-GAAP measure) | 1.5 | % | 5.8 | % | |||||||
| Impact of certain acquisitions and divestitures | — | % | — | % | |||||||
| Net sales organic growth (non-GAAP measure) | 1.5 | % | 5.8 | % |
In August 2026, we identified a cybersecurity incident that affected certain of our information technology systems and resulted in a global disruption to our operations, which impacted our ability to manufacture as well as process and ship customer orders (the cybersecurity incident). We worked diligently, with the assistance of third-party cybersecurity experts, to investigate, assess and contain the impact of the incident and to restore operations. The cybersecurity incident caused significant disruption to our business operations and materially impacted our third quarter financial results. For additional information on the risks related to the cybersecurity incident and its impact on our business, financial condition and results of operations, refer to Part II, Item 1A. of this Quarterly Report on Form 10-Q (this Quarterly Report).
During the third quarter of 2026, the increase in our reported net sales was primarily driven by innovation and strong commercial execution in our Interventional Cardiology and Vascular Therapies (ICVT) business unit, offset by disruptions to manufacturing and order fulfillment resulting from the cybersecurity incident and increased competition within our Electrophysiology business unit as well as a deceleration in the left atrial appendage closure (LAAC) market, impacting WATCHMAN™ procedures. During the first nine months of 2026, the increase in our reported net sales was primarily driven by our ICVT and Electrophysiology business units, offset by increased competition within our Electrophysiology business unit and a deceleration in the LAAC market, impacting WATCHMAN™ procedures. Refer to Results of Operations for a discussion of our net sales by business.
During the third quarter of 2026, the decrease in our reported net income attributable to Boston Scientific common stockholders was primarily driven by disruptions to manufacturing and order fulfillment as well as higher supply chain costs due to idle production time related to the cybersecurity incident and higher litigation-related net charges. During the first nine months of 2026, the increase in our reported net income attributable to Boston Scientific common stockholders was primarily driven by higher net sales and a discrete tax benefit recorded in the first quarter of 2026, offset by higher costs related to the cybersecurity incident. Refer to Tax Rate for additional details pertaining to the discrete tax benefit.
To supplement our unaudited consolidated financial statements prepared on a generally accepted accounting principles in the United States (GAAP) basis, we disclose certain non-GAAP measures, including operational and organic net sales growth, adjusted net income attributable to Boston Scientific common stockholders and adjusted net income per common share - diluted. Operational net sales growth excludes the impact of foreign currency fluctuations. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. There were no applicable acquisitions in the first nine months of 2026 or 2025. Our adjusted net income attributable to Boston Scientific common stockholders and adjusted net income per common share - diluted exclude certa
Showing the first 8K of 63K characters. Open the full section
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.
Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $17.138 billion as of September 30, 2026 and $12.726 billion as of December 31, 2025. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $895 million as of September 30, 2026 compared to $804 million as of December 31, 2025. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $1.097 billion as of September 30, 2026 compared to $982 million as of December 31, 2025. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impacts on our unaudited consolidated statements of operations.
Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of September 30, 2026 or December 31, 2025. As of September 30, 2026, $10.847 billion in aggregate principal amount of our outstanding debt obligations was at fixed interest rates, representing approximately 91% of our total debt, on an amortized cost basis. As of September 30, 2026, our outstanding debt obligations at fixed interest rates were comprised of senior notes.
Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments.
Item 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our President and Chief Executive Officer (CEO) and our Executive Vice President and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of September 30, 2026, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
Previously, we began a multi-year implementation of a new global enterprise resource planning (ERP) system, which will replace our existing system. The implementation has been occurring in phases and will continue over the next several years. As each phase is completed, our related internal controls may change and are updated accordingly. During the third quarter of 2026, there were no changes to our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As future phases are implemented, we expect the changes to have a material impact on our internal controls over financial reporting and we will evaluate whether these process changes necessitate further changes in the design of and testing for effectiveness of internal controls over financial reporting.
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Refer to Note H – Commitments and Contingencies to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.
Item 1A. RISK FACTORS
For a discussion of important risks and uncertainties that may affect our business, financial condition and results of operations, see Item 1A. Risk Factors in our most recent Annual Report on Form 10-K. The risk factors disclosed in our Annual Report on Form 10-K should be read in conjunction with the following updates and are supplemented by the disclosures below:
Business and Operational Risks
We rely on the proper function, availability and security of information technology systems to operate our business and cybersecurity incidents or other breaches of our systems have adversely affected, and could in the future adversely affect, our business, financial condition or results of operations.
We rely on information and operational technology systems, including technology from third party vendors, to manufacture and distribute our products, as well as to process, transmit and store electronic information in our day-to-day operations. Similar to other large multi-national companies, the size and complexity of our IT environment, coupled with advancements in artificial intelligence and sophistication of techniques, make them targets for a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, theft of intellectual property or other significant intentional and unlawful disruption. On August 25, 2026, we identified a cybersecurity incident that affected certain of our information technology systems and resulted in a global disruption to our operations, which impacted our ability to manufacture as well as process and ship customer orders. The cybersecurity incident caused significant disruption to our business operations and materially impacted our results of operations for the third quarter of 2026. While our operations have since been fully restored, we may not recover all of the revenue impacted by the incident and we may experience further impacts, including a potential loss of market share, or other adverse financial, legal, regulatory or reputational impacts. Civil legal claims have been filed, and we may face regulatory scrutiny related to the incident. We are unable to predict the outcome or timeline of these matters or whether additional lawsuits, inquiries or investigations may arise. We also expect to incur increased expenses in connection with our response and remediation of the incident and strengthening of our cybersecurity program. Although we have invested, and expect to continue to invest in measures to address cybersecurity threats, the techniques used in cyberattacks change frequently and may be difficult to anticipate or prevent. These measures may not be effective in preventing future cybersecurity incidents, and any such incident could have a material adverse effect on our business, financial condition or results of operations.
Further, as part of our response and remediation efforts for the incident, we used, and in any future incident may need to use, manual processes or other alternatives to our systems for a period of time. Such alternatives may be less efficient and may increase the risk of errors, delays or data integrity issues, including with respect to information collected or processed during a disruption, which could in turn adversely affect our internal processes and controls, including those supporting financial and operational reporting.
In addition, malicious actors have attempted, and may in the future attempt, to deceive employees, including through various social engineering techniques, to disclose information to gain access to our systems and/or data, and such attempts have from time to time resulted in unauthorized access to certain data, which has required, and may in the future require, us to notify affected individuals or regulators. As the methods of cyber-attacks advance, the steps that we may need to take to investigate cybersecurity incidents may not be immediately clear, and it may take a significant amount of time for such investigations to be completed and full and reliable information about such incidents to be known. Further, adverse impacts to the availability, integrity, or confidentiality of our systems or data could require us to incur additional costs to modify or enhance our systems, or to try to prevent or remediate future cyber-attacks. Modifying or enhancing our systems may result in unanticipated or prolonged disruption events, which could have a material adverse effect on our business operations and financial results.
Interruption of our supply chain or manufacturing operations has adversely affected, and could in the future adversely affect, our business, results of operations and financial condition.
Our products are designed and manufactured in technology centers around the world, either by us or third parties. In most cases, the manufacturing of any specific product is concentrated in one or a few locations. Factors such as a failure to follow specific
internal protocols and procedures, results of regulatory inspections of our manufacturing facilities, equipment malfunction, environmental factors, cybersecurity incidents or damage to one or more of our facilities could adversely affect our ability to manufacture or distribute our products. The August 2026 cybersecurity incident affected certain of our technology systems and resulted in a global disruption to our operations, which impacted our ability to manufacture as well as process and ship customer orders. We may experience additional cyberattacks in the future and/or further impacts resulting from the August 2026 incident. While we resumed our operations within weeks of the incident, in the event of a future interruption to our operations, we may be unable to quickly restore operations or move to alternate means of producing affected products or to meet customer demand. As a result of any such interruptions or delays, we may experience loss of market share, which we may be unable to recapture and harm to our reputation, which could adversely affect our results of operations and financial condition.
Item 5. OTHER INFORMATION
(c)
On August 12, 2026, Michael F. Mahoney, our Chairman and Chief Executive Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Mahoney’s plan covers the sale of 98,814 shares of our common stock to be acquired upon exercise of stock options. Transactions under Mr. Mahoney’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Mahoney’s plan will terminate on the earlier of February 28, 2027, or the date all shares subject to the plan have been sold.
Item 6. EXHIBITS ( documents filed or furnished with this report; # compensatory plans or arrangements)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on November 2, 2026.
| BOSTON SCIENTIFIC CORPORATION | |||||||||||
| By: | /s/ Jonathan Monson | ||||||||||
| Name: | Jonathan Monson | ||||||||||
| Title: | Executive Vice President and Chief Financial Officer |